Tyrosinemia Type 1: A Case Prior to Newborn Screening and the Importance of Early Treatment
Article Sidebar
Main Article Content
Abstract
Abstract
Introduction: Tyrosinemia type 1 (TYR1) is a severe hereditary metabolic disorder caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), leading to the accumulation of toxic metabolites and hepatorenal damage. Without treatment, it may progress to liver failure or hepatocellular carcinoma. Nitisinone is the treatment of choice, as it blocks the formation of toxic compounds. Early diagnosis is critical, particularly in contexts where newborn screening is not yet implemented.
Case report: We present the case of a 2-month-old infant, born to consanguineous parents, who presented with abdominal distension, vomiting, and diarrhea. The patient exhibited severe coagulopathy, metabolic acidosis, and ultrasound findings suggestive of acute abdomen. After transfer to a tertiary care center and completion of metabolic studies, a diagnosis of TYR1 was confirmed. Nitisinone therapy was initiated, with a favorable outcome following a complex stay in the intensive care unit.
Discussion: Although the use of nitisinone has significantly reduced the need for liver transplantation, further studies are needed to better understand its potential long-term neurocognitive effects. Continuous clinical and neuropsychological monitoring is recommended for affected individuals.
Conclusions: Early diagnosis of TYR1 through newborn screening enables prompt initiation of treatment with nitisinone and dietary management, significantly improving survival and reducing the risk of hepatocellular carcinoma. While treatment has dramatically changed the prognosis, uncertainties remain regarding long-term effects, particularly at the neurocognitive level. Comprehensive follow-up, including clinical, metabolic, and neuropsychological assessments, is essential.
Downloads
Article Details
Copyright (c) 2025 Quílez HL, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Grompe M. Disorders of tyrosine metabolism. In: Connor RF, editor. UpToDate. Waltham, MA: Wolters Kluwer; [cited 2025 Mar 23]. Available from: https://www.uptodate.com
Spanish Ministry of Health. National Newborn Screening Program for Congenital Diseases [Internet]. Madrid: Ministry of Health; [cited 2025 Mar 23].
Mohamed S, Kambal MA, Al Jurayyan NA, Al Nemri A, Babiker A, Hasanato R, et al. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy. BMC Res Notes. 2013;6:362. Available from: https://doi.org/10.1186/1756-0500-6-362
Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12):1380–95. Available from: https://doi.org/10.1038/gim.2017.101
Imseis EM, Bynon JS, Thornhill C. Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era. World J Hepatol. 2017;9(9):487–90. Available from: https://doi.org/10.4254/wjh.v9.i9.487
Nitisinone: new drug. Type 1 tyrosinemia: an effective drug. Prescrire Int. 2007;16(88):56–8. Available from: https://pubmed.ncbi.nlm.nih.gov/17458044/
van Ginkel WG, Jahja R, Huijbregts SCJ, Daly A, MacDonald A, De Laet C, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet J Rare Dis. 2016;11:87. Available from: https://doi.org/10.1186/s13023-016-0472-5